Evaluation of procalcitonin levels in nephropathic and non- nephropathic diabetic patients
Nefropatisi olan ve olmayan diyabetli hastalarda prokalsitonin düzeylerinin değerlendirilmesi
Murat Dağdeviren 1 * , Esin Beyan 2, Tanyel S. Dağdeviren 3, Esra Çopuroğlu 2, Yavuz Çağır 2, Özlem Doğan 4, Derun T. Ertuğrul 1, Mustafa Altay 1
1 Sağlık Bilimleri Üniversitesi, Keçiören Sağlık Uygulama ve Araştırma Merkezi, Endokrinoloji ve Metabolizma Hastalıkları Kliniği, Ankara, Türkiye
2 Sağlık Bilimleri Üniversitesi, Keçiören Sağlık Uygulama ve Araştırma Merkezi, İç Hastalıkları Kliniği, Ankara, Türkiye
3 Sağlık Bilimleri Üniversitesi, Keçiören Sağlık Uygulama ve Araştırma Merkezi, Aile Hekimliği Kliniği, Ankara, Türkiye
4 Ankara Üniversitesi Tıp Fakültesi, Tıbbi Biyokimya Anabilim Dalı, Ankara, Türkiye
* Corresponding Author
Ortadogu Tıp Derg, Volume 10, Issue 4, pp. 516-522
https://doi.org/10.21601/ortadogutipdergisi.365431
OPEN ACCESS
Download Full Text (PDF)
Abstract
Aim: To investigate how serum procalcitonin (PCT) levels are affected in diabetic patients with and without nephropathy, and to determine whether PCT may be indicative of an inflammation in these patients.
Material and Method: The study included 175 patients [75 diabetic nephropathy (group 1), 75 non-nephropathy diabetic (group 2) and 25 non-diabetic nephropathy (group 3)], and 75 healthy volunteers. Serum and urinary creatinine, serum high sensitive C-reactive protein (HsCRP), PCT, white blood cell, neutrophil, HbA1c and urinary protein values were obtained from patients and control groups. Urinary protein / creatinine ratio and eGFR were calculated.
Results: There was no significant difference of PCT values between groups 1, 2, 3 and control group (0.20-0.19-0.23 and 0.19, respectively) (p>0.05). HsCRP levels of all 3 patient groups were higher than the control group (p<0.001). A negative correlation was found between eGFR values, PCT (p<0.001; r = -0.475) and HsCRP (p<0.001; r= -0.415) values in nephropathy patients (diabetic and non-diabetic). Patients with diabetic nephropathy were compared to those with a eGFR of 60 ml/min or more with those below eGFR 60 ml/min. When the eGFR values were lower than 60 ml/min, the HsCRP values were higher (p<0.05); there was no difference between the PCT values (p>0.05).
Conclusion: There was no significant increase in PCT values of diabetic and diabetic nephropathy patients. However, there was a negative correlation between PCT level and eGFR. This suggests that there may be an increase in PCT values, especially in advanced chronic renal disease, regardless of the etiology.
Öz
Amaç: Nefropatisi olan ve olmayan diyabetli hastalarda serum prokalsitonin (PCT) düzeylerinin nasıl etkilendiğini araştırarak bu hastalarda PCT’nin bir enflamasyon göstergesi olup olamayacağını belirlemektir.
Gereç ve Yöntem: Çalışmaya 175 hasta [75 diyabetik nefropati (grup 1), 75 nefropatisi olmayan diyabetik (grup 2) ve 25 non-diyabetik nefropati (grup 3)] ve 75 sağlıklı gönüllü dahil edildi. Hasta ve kontrol gruplarının serum ve üriner kreatinin, serum high sensitive C-reaktif protein (hsCRP), PCT, beyaz küre, nötrofil, HbA1c ve üriner protein değerleri elde edildi. Üriner protein/kreatinin oranı ve eGFR hesaplandı.
Bulgular: Grup 1, 2 ve 3 ile kontrol grubunun PCT değerleri (sırasıyla 0,20-0,19-0,23 ve 0,19) arasında anlamlı bir fark yoktu (p>0,05). Her 3 hasta grubunun hsCRP düzeyleri ise kontrol grubundan yüksekti (p<0,001). Nefropatili hastaların (diyabetik ve non-diyabetik) GFR değerleri ile PCT (p<0,001; r = -0,475) ve hsCRP (p<0,001; r= -0,415) değerleri arasında negatif korelasyon saptandı. Diyabetik nefropatili hastalarda GFR 60 ml/dk’nın altında olanlarla GFR 60 ml/dk ve üzerinde olanlar karşılaştırıldığında; GFR değerleri 60 ml/dk’dan düşük olanların hsCRP değerleri daha yüksek iken (p<0,05); PCT değerleri arasında fark yoktu (p>0,05).
Sonuç: Diyabetli ve diyabetik nefropatili hastaların PCT değerlerinde anlamlı bir artış yoktu. Ancak PCT düzeyi ile GFR arasında negatif korelasyon mevcuttu. Bu durum özellikle ileri evre kronik böbrek hastalığında, etiyolojik nedenden bağımsız olarak PCT değerlerinde artış olabileceğini göstermektedir.
- Zimmet P, Williams J, de Courten M. Diagnosis and classification of diabetes mellitus. Eds: JAM Wass, SM Shalet, E Gale, S Amiel. Oxford Textbook of Endocrinology and Diabetes. Oxford, New York, Oxford University Press, pp 1635-46.
- Lopes AA. End-Stage Renal Disease Due To Diabetes In Racial/Ethnic Minorities and Disadvantaged Populations. Ethnicity & Disease, 2009; 19: 1-51
- Kurt M, Atmaca A, Gürlek A. Diyabetik nefropati. Hacettepe Tıp Dergisi 2004; 35: 12-7.
- Gross JL, De Azevedo MD, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic Nephropathy: Diagnosis, Prevention, And Treatment. Diabetes Care 2005; 28:176–88.
- Wiwanitkit V. Diabetic nephropathy without hyperglycemia. Diab Met Syndr Clin Res Rev 2009; 3: 118-9.
- Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohoun C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993;341:515-8.
- Becker KL, Nylen ES, White JC, Muller B, Snider Jr RH. Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 2004; 89:1512–25.
- Müller B, White JC, Nylé ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab 2001; 86:396–404.
- Scire C, Cavagna L, Perotti C, Buruschi E, Caporali R, Montecucco C. Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol 2006; 24: 123-128.
- Ebherhard OK, Haubitz M, Brunkhorst FM, Kliem V, Koch KM, Brunkhorst R. Usefulness of procalcitonin for diferantiation between activity of systemic autoimmun disease and invasive bacterial infection. Arthiritis Rheum 1997; 40:125-6.
- Okada Y, Minakami H, Tomamasa T, et al. Serum procalcitonin concentration in patients with Kawasaki disease . J Infect 2004; 48: 199-205.
- Schwenger V, Sis J, Breitbart A, Andrassy K. CRP levels in autoimmune disease can be specified by measurement of procalcitonin. İnfection 1998; 26:274-6.
- Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:16405.
- Schindler R. Causes and therapy of microinflammation in renal failure. Nephrol Dial Transplant. 2004; 19(5):34-40.
- Nylen ES, Whang KT, Snider RH Jr, Steinwald PM, White JC, Becker KL. Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med 1998; 26: 1001-6.
- Abbasi A, Corpeleijn E, Postmus D, et al. Plasma procalcitonin is associated with obesity, insulin resistance, and the metabolic syndrome. J Clin Endocrinol Metab 2010; 95:26–31
- Becker KL, Nylén ES, White JC, Müller B, Snider RH Jr. Clinical review 167: procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 2004;89:1512–25
- Abbasi A, Corpeleijn E, Postmus D, et al. Plasma procalcitonin and risk of type 2 diabetes in the general population. Diabetologia. 2011;54(9):2463-5
- Aksu NM, Aksoy DY, Akkaş M, et al. 25-OH-Vitamin D and procalcitonin levels after correction of acute hyperglycemia. Med Sci Monit 2013; 19:264-8.
- Wan ZM, Chen WY, Lu ML, et al. Higher procalcitonin level in diabetic nephropathy patients compared with healthy volunteer. Sichuan Da Xue Xue Bao Yi Xue Ban. 2014; 45(3):442-6.
- Opatrná S, Klaboch J, Opatrný K Jr, et al. Procalcitonin levels in peritoneal dialysis patients. Perit Dial Int. 2005; 25(5):470-2.
- Steinbach G, Bölke E, Grünert A, Störck M, Orth K. Procalcitonin in patients with acute and chronic renal insufficiency. Wien Klin Wochenschr. 2004; 116(24):849-53.
- Meisner M, Schmidt J, Hüttner H, Tschaikowsky K. The natural elimination rate of procalcitonin in patients with normal and impaired renal function. Intensive Care Med. 2000; 26(2):212-6.
- Meisner M, Lohs T, Huettemann E, Schmidt J, Hueller M, Reinhart K. The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function. Eur J Anaesthesial 2001; 18:79-87.
- Sitter T, Schmidt M, Schneider S, Schiffl H. Differential diagnosis of bacterial infection and inflammatory response in kidney diseases using procalcitonin. JN 2002; 15: 297-301.
- Herget-Rosenthal S, Klein T, Marggrafy G, et al. Modulation and Source of Procalcitonin in Reduced Renal Function and Renal Replacement Therapy. Scand J Immunol 2005; 61:180-6.
- Steinbach G, Bölke E, Grünert A, Störck M, Orth K. Procalcitonin in patients with acute and chronic renal insufficiency. Wien Klin Wochenschr. 2004; 116(24):849-53.
- Yuan G, Zhou L, Tang J, et al. Serum CRP levels are equally elevated in newly diagnosed type 2 diabetes and impaired glucose tolerance and related to adiponectin levels and insulin sensitivity. Diabetes Res Clin Pract. 2006; 72(3):244-50.
- Stuveling EM, Hillege HL, Bakker SJ, Gans RO, De Jong PE, De Zeeuw D. C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int. 2003; 63(2):654-61.
- Tbahriti HF, Meknassi D, Moussaoui R, et al. Inflammatory status in chronic renal failure: The role of homocysteinemia and pro-inflammatory cytokines. World J Nephrol. 2013; 2(2):31-7.
Citation
Dağdeviren M, Beyan E, Dağdeviren TS, Çopuroğlu E, Çağır Y, Doğan Ö, et al. Evaluation of procalcitonin levels in nephropathic and non- nephropathic diabetic patients. Ortadogu Tıp Derg. 2018;10(4):516-22.
https://doi.org/10.21601/ortadogutipdergisi.365431
Dağdeviren, M., Beyan, E., Dağdeviren, T. S., Çopuroğlu, E., Çağır, Y., Doğan, Ö., Ertuğrul, D. T., & Altay, M. (2018). Evaluation of procalcitonin levels in nephropathic and non- nephropathic diabetic patients.
Ortadoğu Tıp Dergisi, 10(4), 516-522.
https://doi.org/10.21601/ortadogutipdergisi.365431
Dağdeviren, M., Beyan, E., Dağdeviren, T. S., Çopuroğlu, E., Çağır, Y., Doğan, Ö., . . . Altay, M. (2018). Evaluation of procalcitonin levels in nephropathic and non- nephropathic diabetic patients.
Ortadoğu Tıp Dergisi, 10(4), pp. 516-522.
https://doi.org/10.21601/ortadogutipdergisi.365431
Dağdeviren, Murat, Esin Beyan, Tanyel S. Dağdeviren, Esra Çopuroğlu, Yavuz Çağır, Özlem Doğan, Derun T. Ertuğrul, and Mustafa Altay. "Evaluation of procalcitonin levels in nephropathic and non- nephropathic diabetic patients".
Ortadoğu Tıp Dergisi 2018 10 no. 4 (2018): 516-522.
https://doi.org/10.21601/ortadogutipdergisi.365431